Axa Private Equity Buys Active Ingredient Business

Health and nutrition product firm Atrium (Quebec City) says it has agreed to sell its active ingredient and specialty chemical division to Axa Private Equity (Paris) for $155 million in cash. The deal is expected to generate total proceeds of more than $165 million, subject to working capital adjustments, and is expected to close by mid-May, pending customary approvals. Charles Boulanger will continue as president of the division, which will also retain its current management team, Atrium says. The deal does not include Atrium’s Quebec City manufacturing...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers